Ibrance
E474934
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
CDK4/6 inhibitor
ⓘ
cancer medication ⓘ pharmaceutical drug ⓘ targeted therapy ⓘ |
| belongsToDrugClass |
antineoplastic agents
ⓘ
protein kinase inhibitors ⓘ |
| hasActiveIngredient | palbociclib NERFINISHED ⓘ |
| hasAdministrationCycle | 28-day cycle ⓘ |
| hasATCCode | L01EF01 ⓘ |
| hasBlackBoxWarning | none ⓘ |
| hasCommonAdverseEffect |
anemia
ⓘ
diarrhea ⓘ fatigue ⓘ infections ⓘ leukopenia ⓘ nausea ⓘ neutropenia ⓘ stomatitis ⓘ thrombocytopenia ⓘ |
| hasCommonDoseStrength |
100 mg
ⓘ
125 mg ⓘ 75 mg ⓘ |
| hasDosageForm |
capsule
ⓘ
tablet ⓘ |
| hasDosingSchedule | 21 days on treatment followed by 7 days off ⓘ |
| hasFDAApprovalStatus | approved ⓘ |
| hasGenericName | palbociclib NERFINISHED ⓘ |
| hasInitialFDAApprovalYear | 2015 ⓘ |
| hasINN | palbociclib NERFINISHED ⓘ |
| hasPregnancyCategory | can cause fetal harm ⓘ |
| hasRegulatoryAgency |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| isApprovedFor |
men with HR-positive, HER2-negative advanced or metastatic breast cancer
ⓘ
postmenopausal women with HR-positive, HER2-negative advanced breast cancer ⓘ |
| isContraindicatedWith | severe hypersensitivity to palbociclib ⓘ |
| isIndicatedFor |
HER2-negative breast cancer
ⓘ
advanced breast cancer ⓘ hormone receptor–positive breast cancer ⓘ metastatic breast cancer ⓘ |
| isManufacturedBy | Pfizer NERFINISHED ⓘ |
| isMetabolizedBy | CYP3A ⓘ |
| isTakenWithFood | yes ⓘ |
| isUsedInCombinationWith |
fulvestrant
NERFINISHED
ⓘ
letrozole NERFINISHED ⓘ |
| mechanismOfAction | inhibits CDK4 and CDK6 to block cell cycle progression from G1 to S phase ⓘ |
| targets |
cyclin-dependent kinase 4
NERFINISHED
ⓘ
cyclin-dependent kinase 6 NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.